A promising treatment for metastasized prostate cancer

Spread the love

A hopeful treatment for metastasized prostate cancer

Prostate cancer starts in the cells of the prostate, an organ located in the male pelvis, below the bladder and in front of the rectum. This cancer can then spread to other areas of the body.

A new precision treatment approved by Health Canada for metastatic castration-resistant prostate cancer (mCRPC) could allow terminally ill patients to see their lives extended.< /p>

Dr. Fred Saad, full professor of surgery and urology at the University of Montreal Hospital Center, is excited about the new cutting-edge therapy that will give a new treatment option for patients with mCRPC that has spread to other parts of the body despite numerous treatments.

It gives patients hope to maintain their quality of life and prolong their survival, says Professor Saad.

Dr. Fred Saad believes the new therapy will provide a new treatment option for patients with metastasized prostate cancer.

The new therapeutic approach uses nuclear medicine to attack only cancer cells without damaging organs in the body that are not affected by cancer.

In the first time, oncologists very precisely scan the patient's cancer and then inject radioligands into the blood. A radioligand is composed of a targeting molecule capable of recognizing the patient's cancer cells, attaching to them and releasing a radioactive particle which will then destroy them.

“It's really the treatment we've been dreaming of and which allows us to specifically target a patient's cancer. ”

— Dr. Fred Saad

Clinical trials have shown that, on average, the therapy reduces the progression of metastases by 50% and increases 40% chance of patient survival.

The results are sometimes even more spectacular, as was the case for Yvan Laniel, who had been treating prostate cancer for 22 years.

Yvan Laniel underwent experimental radioligand therapy.

The 78-year-old man underwent all the treatments offered to him, standard and experimental. While they all worked well, these treatments only prolonged his life. In 2018, however, his luck seemed to turn: metastases were present all over his body.

That's when his doctor offered him the experimental radioligand therapy.

A new therapeutic approach is very promising. It uses nuclear medicine to attack only diseased cells, without attacking healthy cells. And in some cases, the result is exceptional. Report by Normand Grondin.

From the first treatment, the metastases began to resolve and, 18 months later, they were all gone. It was huge! It was serious and very effective, but I didn't know how long it would last, explains M Laniel.

If for the vast majority of patients remission remains temporary, luck still smiles on Mr. Laniel.

“To my great surprise, I'm in the 2% that responded the best to the treatment. It might look like a miracle. And I feel like that too, which is to say, I feel very good. Really.

—Yvan Laniel

  • Approximately 24,600 men will be diagnosed with prostate cancer in 2022 in the country. It is the most common cancer in men and the 3rd leading cause of death from cancer in Canadians.
  • According to Health Canada, 1 in 7 men will be diagnosed with prostate cancer in their lifetime. life and almost all prostate cancers (99%) occur in men aged 50 and over. Many suffer from it without knowing it.
  • The chances of survival for men with metastatic prostate cancer five years after diagnosis are currently 3 in 10.

If the therapy is approved for severe cases of prostate cancer, it could eventually help treat less advanced cancers.

We want to see whether it will be even more effective if we start it even earlier. You have to make sure it's safe first, says Dr. Fred Saad.

At the moment, the therapy is not ;is reimbursed by any health system in Canada.

With information from Normand Grondin.

Previous Article
Next Article